TY - JOUR
T1 - Using Latent Class Analysis to Identify Different Clinical Profiles Among Patients With Advanced Heart Failure
AU - Blum, Moritz
AU - McKendrick, Karen
AU - Gelfman, Laura P.
AU - Pinney, Sean P.
AU - Goldstein, Nathan E.
N1 - Funding Information:
The WISDOM trial was supported by a grant from the National Heart, Lung, and Blood Institute ( R01HL102084 ) and the Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai ( 5P30AG028741 ). LPG received support from the National Institute on Aging (K23AG049930) and the Sojourns Scholars Leadership Award from the Cambia Health Foundation.
Funding Information:
The WISDOM trial was supported by a grant from the National Heart, Lung, and Blood Institute (R01HL102084) and the Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai (5P30AG028741). LPG received support from the National Institute on Aging (K23AG049930) and the Sojourns Scholars Leadership Award from the Cambia Health Foundation. SP is a consultant to Abbott, ADS, Ancora Heart, CareDx, Medtronic, Procyrion, Transmedics, and Valgen Medtech outside of this work. All other authors have nothing to disclose. The authors would like to thank Harriet Mather, Mathew D. Hutchinson, Rachel Lampert, Hannah I. Lipman, Daniel D. Matlock, Jacob J. Strand, Keith M. Swetz, Jill Kalman, Jean S. Kutner and R. Sean Morrison for their contribution to the success of the WISDOM trial.
Publisher Copyright:
© 2022 American Academy of Hospice and Palliative Medicine
PY - 2023/2
Y1 - 2023/2
N2 - Context: Although palliative care is guideline-indicated for patients with advanced heart failure (HF), the scarcity of a specialty-trained palliative care workforce demands better identification of patients who are most burdened by the disease Objectives: We sought to identify latent subgroups with variations regarding symptom burden, functional status, and multimorbidity in an advanced HF population. Methods: We performed a latent class analysis (LCA) of baseline data from a trial enrolling advanced HF patients. As LCA input variables, we chose indicators of HF severity, physical and psychological symptom burden, functional status, and the number of comorbidities. Results: Among 563 patients, two subgroups emerged from LCA, Class A (352 [62.5%]) and Class B (211 [37.5%]). Patients in Class A were less often classified as NYHA class III or IV (88.0% vs. 97.5%, P < 0.001), as compared to Class B patients. Class A patients had fewer symptoms, fewer comorbidities, only 25.9% had impairments in activities of daily living (ADL), and virtually none suffered from clinically significant anxiety (0.4%) or depression (0.9%). In Class B, every patient reported more than three symptoms, almost all patients (92.6%) had some impairment in ADL, and nearly a third had anxiety (30.2%) or depression (28.3%). All-cause mortality after 12 months was higher in Class B, as compared to Class A (18.5% vs. 12.5%, P = 0.047). Conclusion: Among advanced HF patients, we identified a distinct subgroup characterized by a conjunction of high symptom burden, anxiety, depression, multimorbidity, and functional status impairment, which might profit particularly from palliative care interventions.
AB - Context: Although palliative care is guideline-indicated for patients with advanced heart failure (HF), the scarcity of a specialty-trained palliative care workforce demands better identification of patients who are most burdened by the disease Objectives: We sought to identify latent subgroups with variations regarding symptom burden, functional status, and multimorbidity in an advanced HF population. Methods: We performed a latent class analysis (LCA) of baseline data from a trial enrolling advanced HF patients. As LCA input variables, we chose indicators of HF severity, physical and psychological symptom burden, functional status, and the number of comorbidities. Results: Among 563 patients, two subgroups emerged from LCA, Class A (352 [62.5%]) and Class B (211 [37.5%]). Patients in Class A were less often classified as NYHA class III or IV (88.0% vs. 97.5%, P < 0.001), as compared to Class B patients. Class A patients had fewer symptoms, fewer comorbidities, only 25.9% had impairments in activities of daily living (ADL), and virtually none suffered from clinically significant anxiety (0.4%) or depression (0.9%). In Class B, every patient reported more than three symptoms, almost all patients (92.6%) had some impairment in ADL, and nearly a third had anxiety (30.2%) or depression (28.3%). All-cause mortality after 12 months was higher in Class B, as compared to Class A (18.5% vs. 12.5%, P = 0.047). Conclusion: Among advanced HF patients, we identified a distinct subgroup characterized by a conjunction of high symptom burden, anxiety, depression, multimorbidity, and functional status impairment, which might profit particularly from palliative care interventions.
KW - Advanced heart failure
KW - activities of daily living
KW - anxiety
KW - depression
KW - functional status
KW - latent class analysis
KW - multimorbidity
KW - symptom burden
UR - http://www.scopus.com/inward/record.url?scp=85142524881&partnerID=8YFLogxK
U2 - 10.1016/j.jpainsymman.2022.10.011
DO - 10.1016/j.jpainsymman.2022.10.011
M3 - Article
AN - SCOPUS:85142524881
SN - 0885-3924
VL - 65
SP - 111
EP - 119
JO - Journal of Pain and Symptom Management
JF - Journal of Pain and Symptom Management
IS - 2
ER -